An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema

Abstract

We have shown that MTX is an effective, well-tolerated treatment for moderate-to-severe atopic eczema, and response appears to compare favourably with other second-line therapies. A randomized, controlled trial is now warranted.

Systemic treatment of adult atopic dermatitis

“…A retrospective study reported a response in 75% of patients after receiving methotrexate for three months, 14 and a prospective trial confirmed a significant treatment benefit (>50% improvement) for most patients after a similar duration. 15 A recently published RCT compared 12 weeks' treatment with methotrexate or azathioprine in 42 patients. 16 Both showed clinically relevant therapeutic benefit with similar response rates, thereby indicating …”

Atopic dermatitis: Therapeutic concepts evolving from new pathophysiologic insights

“…A recent open-label, dose-escalating study in 12 adult patients with severe AD demonstrated a 52% improvement in the clinical score over baseline values at week 24, and only 1 patient withdrew from further treatment because of adverse events, a result that is clinically meaningful. 96 By using the same scoring system (six-area, six-sign SD score), azathioprine showed a 37% improvement over baseline values at week 12 (placebo 20%) in a double-blind, placebo-controlled study in patients with moderateto-severe AD older than 16 years, 97 thus confirming efficacy as assessed during an earlier trial. 98 Although adverse events, such as leucopenia and increased liver transaminase levels, need to be carefully monitored, these data indicate that azathioprine is effective in AD.…”

The Turkish guideline for the diagnosis and management of atopic dermatitis-2018

“…İstenen etki elde edildikten sonra azaltılıp bırakılması önerilmektedir. Psoriazisli çocuk hastalardaki veriler MTX'in çocuklarda güvenilir olduğu yönündedir 125 .…”